Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Protalix BioTherapeutics, Inc. (PLX) had Receiveable Turnover of 12.42 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$65.49M |
|
$8.31M |
|
$22.98M |
|
$42.51M |
|
$55.03M |
|
$10.46M |
|
$-1.89M |
|
$8.57M |
|
$8.57M |
|
$8.31M |
|
$8.31M |
|
$8.31M |
|
$8.31M |
|
$10.46M |
|
$11.92M |
|
67.51M |
|
82.42M |
|
$0.12 |
|
$0.09 |
|
| Balance Sheet Financials | |
$69.93M |
|
$4.97M |
|
$14.50M |
|
$84.43M |
|
$45.53M |
|
-- |
|
$5.33M |
|
$50.87M |
|
$33.57M |
|
$33.57M |
|
$33.57M |
|
72.95M |
|
| Cash Flow Statement Financials | |
$-1.32M |
|
$-16.71M |
|
$24.67M |
|
$17.11M |
|
$23.63M |
|
$6.52M |
|
$3.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.54 |
|
-- |
|
-- |
|
-- |
|
0.60 |
|
64.91% |
|
15.97% |
|
15.97% |
|
18.20% |
|
13.08% |
|
12.69% |
|
$-2.47M |
|
-- |
|
-- |
|
-- |
|
0.78 |
|
1.21 |
|
|
Receiveable Turnover |
12.42 |
29.38 |
|
24.76% |
|
24.76% |
|
9.84% |
|
24.76% |
|
$0.46 |
|
$-0.03 |
|
$-0.02 |
|